Navigation Links
Stepped-up vaccine series for hepatitis B is effective during pregnancy
Date:6/27/2011

DALLAS June 28, 2011 UT Southwestern Medical Center maternal-fetal specialists have confirmed a potential new protocol to protect pregnant women who are at risk for hepatitis B, a health problem that affects 2 billion people worldwide.

An accelerated hepatitis B vaccination schedule for high-risk pregnant women was found effective and well-tolerated. The findings appear in the journal Obstetrics & Gynecology.

While the normal three-shot regimen of hepatitis B vaccine for adults given over a six-month period has long been recommended for pregnant women, that schedule often proved unmanageable in the course of a pregnancy.

"It's difficult to get all three doses in pregnancy, and people tend to get lost to follow-up, especially high-risk populations," said Dr. Jeanne Sheffield, associate professor of obstetrics and gynecology at UT Southwestern and lead author of the study.

The research team stepped up the process for pregnant women and used the normal three-shot dosage given to adults over a 12-week period. That regimen is the shortest recommended schedule in nonpregnant adults that still offers protective long-term immunity.

"Now that we've shown it's efficacious in pregnancy, people are interested," said Dr. Sheffield, who also heads UT Southwestern's maternal-fetal medicine fellowship program. "We've already received a number of requests for our specific protocol from physicians who see high-risk patients and are interested in starting a vaccination program."

In the U.S., nearly 1.5 million people live with chronic hepatitis B infection, and it is the underlying cause of 3,000 deaths per year. The American College of Obstetricians and Gynecologists recommended in 1993 and in 2007 that pregnant women at risk for hepatitis B should receive vaccination.

Dr. Sheffield said, however, that health care providers seldom offer the hepatitis B vaccine series to reproductive-aged women because of lack of physician and patient education, patients' fear of vaccination and its purported side effects, and the overall reluctance to vaccinate pregnant women.

Even though the Centers for Disease Control and Prevention reports pregnancy is not a contraindication to hepatitis B vaccine, limited data were available on its use in pregnancy.

In the current study, conducted at Parkland Memorial Hospital, researchers enrolled high-risk women with a current diagnosis of a sexually transmitted disease, injection drug use or both, over a six-year period. Of 200 women enrolled, 168 received all three doses of the vaccine.

Researchers found that race, maternal age, tobacco and alcohol use, and gestational age at first vaccination did not affect seroconversion rates the development of antibodies against hepatitis B using the accelerated schedule. Obesity had a negative influence, however.

The accelerated schedule in pregnancy had seroconversion rates (90 percent) that were comparable to the standard schedule in healthy adults. The study also showed no increase in preterm delivery rates or neonatal intensive care admissions.

"The vaccine was well-tolerated in our pregnant women, and no serious adverse events were reported," Dr. Sheffield said. "Initial concerns about the ability of a pregnant woman to mount an effective immune response to a vaccine are largely unfounded. It's doable."


'/>"/>

Contact: Robin Russell
robin.russel@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Rotavirus vaccine greatly reduced gastroenteritis hospitalizations in children
2. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
3. Mayo Clinic researchers use human vaccine to cure prostate cancer in mice
4. New approach to cancer vaccines proves successful in early studies
5. HPV Vaccine May Cut Rate of Cervical Cancer Precursors
6. Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors
7. Most U.S. Kids Get Recommended Vaccines: CDC
8. Decade of vaccines has potential to save lives, but challenges ahead
9. U-M researchers advocate national strategic approach to therapeutic cancer vaccines
10. Universal flu vaccine clinical trials show promise
11. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Facing medical ... father Ezra Clark is taking advantage of a new benefit for employees that is ... means a lot that the company supports me and other employees as new parents. ...
(Date:7/24/2017)... ... July 24, 2017 , ... ...      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, ... celebrate the structural topping out of the new Destination Medical Building located ...
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... under the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted ... of California Department of Health Care Services, will facilitate the development of a ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... already work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement ... and cost of the care members and patients receive. The agreement also signifies ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
Breaking Medicine Technology: